

Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

**Aspen Medical - SSTP
Approval**

I, Christopher Paul Burgess, Chief Health Officer:

- (a) under section 254(1) of the Act, approve each Scheduled substance treatment protocol specified in Schedule A;
- (b) under section 254(3) of the Act, state that each Schedule substance treatment protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this instrument.

Dated 28 August 2025

Chief Health Officer

Schedule A

Title	Publication Date	Author
Aspen Medical - SSTP	27 August 2025	Medicines and Poisons, Northern Territory Government, NT Health

Aspen Medical - SSTP

Areas Applicable	NT Wide	
Health Professionals authorised by this SSTP	Nurses, and Paramedics employed by or contracted to Aspen Medical Pty Ltd (ABN 32 105 250 413)	
Scheduled Substance(s)	Adrenaline	Metoclopramide
	Amiodarone	Midazolam
	Amoxicillin	Naloxone
	Atropine	Neomycin
	Benztropine	Nystatin
	Cefalexin	Olanzapine
	Ceftriaxone	Ondansetron
	Chloramphenicol	Promethazine
	Clavulanic Acid	Salbutamol
	Clopidogrel	Silver Sulfadiazine
	Diazepam	Triamcinolone
	Enoxaparin	Vaccine - diphtheria
	Furosemide	Vaccine - hepatitis A
	Glucagon	Vaccine - hepatitis B
	Glyceryl Trinitrate	Vaccine - influenza
	Hyoscine butyl-bromide	Vaccine - tetanus
	Hydrocortisone	
	Ipratropium	Schedule 8 Medicines
	Ketorolac	Fentanyl
	Lidocaine	Morphine
	Methoxyflurane	

Indication, Dose, Route, Frequency	<ul style="list-style-type: none"> Individual substances, or combinations of substances, are to be used according to the indication for which they are being administered as outlined in the Aspen Medical Pty Ltd Clinical Practice Protocols as in force from time to time. Any administration of these substances outside of the approved Guidelines must be under direct instruction of a Medical Practitioner. 		
Contraindications and/or Exclusions*	<ul style="list-style-type: none"> Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol Any contraindications or exclusions as outlined in the individual scheduled substance product information Any contraindication or exclusions as outlined in Aspen Medical Pty Ltd Clinical Practice Protocols as in force from time to time. 		
Health Professional Accreditation Requirements	<p><u>Nurses must:</u></p> <ul style="list-style-type: none"> Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients Maintain continuing professional development related to skills and competencies required for delivery of medicines <p><u>Paramedics must:</u></p> <ul style="list-style-type: none"> Hold registration with the Paramedicine Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients Maintain continuing professional development related to skills and competencies required for delivery of medicines 		
Chief Health Officer	Signature	Name	Date
	EDOC2025/175577	Christopher Paul Burgess	28/08/2025
Period of effect	This SSTP is in effect until 28/08/2027 unless revoked earlier		
<p>References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer’s product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration</p>			